Staging and neuroprogression in bipolar disorder

Current Psychiatry Reports

Volumn 14, Issue 6, 2012, Pages 667-675

  Fries, Gabriel Rodrigo ^a,b   Pfaffenseller, Bianca ^a,b   Stertz, Laura ^a,b   Paz, André Vinicius Contri ^a   Dargél, Aroldo Ayub ^a,b   Kunz, Maurício ^a,b   Kapczinski, Flávio ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Allostatic load; BD; Biomarkers; Bipolar disorder; Cellular resilience; Clinical staging model; Neuroplasticity; Neuroprogression; Psychiatry; Remission; Staging; Treatment

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; MOOD STABILIZER; NEUROTROPHIN;

BIPOLAR DISORDER; CHROMOSOME SIZE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; ENDOPLASMIC RETICULUM; HUMAN; MITOCHONDRION; NERVE CELL PLASTICITY; NEUROANATOMY; OXIDATIVE STRESS; REMISSION; REVIEW; STAGING; TELOMERE;

ALLOSTASIS; BIOLOGICAL MARKERS; BIPOLAR DISORDER; BRAIN; DISEASE PROGRESSION; HUMANS; STRESS, PHYSIOLOGICAL;

EID: 84870847452     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-012-0319-2     Document Type: Review

References (97)

1. Post RM, Fleming J, Kapczinski F. Neurobiological correlates of illness progression in the recurrent affective disorders. J Psychiatr Res. 2012;46(5):561-73.
2. Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804-17.
3. Kapczinski F, Vieta E, Andreazza AC, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev. 2008;32(4):675-92.
4. Berk M, Brnabic A, Dodd S, et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord. 2011;13(1):87-98.
5. Kessing LV, Andersen PK, Mortensen PB. Predictors of recurrence in affective disorder. A case register study. J Affect Disord. 1998;49(2):101-8. (Pubitemid 28201999)
6. Roy-Byrne P, Post RM, Uhde TW, Porcu T, Davis D. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatr Scand Suppl. 1985;317:1-34. (Pubitemid 15231666)
7. Ketter TA, Houston JP, Adams DH, et al. Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. J Clin Psychiatry. 2006;67(1):95-101. (Pubitemid 43213288)
8. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry. 1999;156(8):1264-6. (Pubitemid 29374889)
9. Scott J, Paykel E, Morriss R, et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br J Psychiatry. 2006;188:313-20.
10. Reinares M, Colom F, Rosa AR, et al. The impact of staging bipolar disorder on treatment outcome of family psychoeducation. J Affect Disord. 2010;123(1-3):81-6.
11. Matza LS, Rajagopalan KS, Thompson CL, de Lissovoy G. Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. J Clin Psychiatry. 2005;66(11):1432-40. (Pubitemid 41779542)
12. Rosa AR, González-Ortega I, González-Pinto A, et al. Oneyear psychosocial functioning in patients in the early vs. late stage of bipolar disorder. Acta Psychiatr Scand. 2012;125 (4):335-41.
13. Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand Suppl. 2007;434:17-26. (Pubitemid 47231065)
14. Kessing LV, Andersen PK. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry. 2004;75(12):1662-6. (Pubitemid 39611460)
15. Hawton K, Sutton L, Haw C, Sinclair J, Harriss L. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. J Clin Psychiatry. 2005;66(6):693-704. (Pubitemid 40942414)
16. Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry. 2002;63(11):985-91. (Pubitemid 35388056)
17. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry. 1992;149 (8):999-1010.
18. Vieta E, Reinares M, Rosa AR. Staging bipolar disorder. Neurotox Res. 2011;19(2):279-85.
19. Vieta E, Popovic D, Rosa AR, et al. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. Eur Psychiatry 2012. doi:10.1016/j.eurpsy.2011.11.007.
20. McEwen BS, Wingfield JC. The concept of allostasis in biology and biomedicine. Horm Behav. 2003;43(1):2-15. (Pubitemid 36293268)
21. Strakowski SM, Delbello MP, Adler CM. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol Psychiatry. 2005;10(1):105-16. (Pubitemid 40139591)
22. Lyoo IK, Sung YH, Dager SR, et al. Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord. 2006;8(1):65-74. (Pubitemid 43356022)
23. Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry. 2001;49(9):741-52. (Pubitemid 32452295)
24. López-Larson MP, DelBello MP, Zimmerman ME, Schwiers ML, Strakowski SM. Regional prefrontal gray and white matter abnormalities in bipolar disorder. Biol Psychiatry. 2002;52(2):93-100. (Pubitemid 34756554)
25. Ongür D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA. 1998;95(22):13290-5. (Pubitemid 28509564)
26. Sassi RB, Brambilla P, Hatch JP, et al. Reduced left anterior cingulate volumes in untreated bipolar patients. Biol Psychiatry. 2004;56(7):467-75. (Pubitemid 39278243)
27. Doris A, Belton E, Ebmeier KP, Glabus MF, Marshall I. Reduction of cingulate gray matter density in poor outcome bipolar illness. Psychiatry Res. 2004;130(2):153-9. (Pubitemid 38366436)
28. Drevets WC, Price JL, Simpson JR, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386 (6627):824-7. (Pubitemid 27181254)
29. Bora E, Fornito A, Yücel M, Pantelis C. Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder. Biol Psychiatry. 2010;67(11):1097-105.
30. Rosso IM, Killgore WD, Cintron CM, et al. Reduced amygdala volumes in first-episode bipolar disorder and correlation with cerebral white matter. Biol Psychiatry. 2007;61(6):743-9. (Pubitemid 46330244)
31. Javadapour A, Malhi GS, Ivanovski B, et al. Hippocampal volumes in adults with bipolar disorder. J Neuropsychiatry Clin Neurosci. 2010;22(1):55-62.
32. Berk M, Hallam K, Malhi GS, et al. Evidence and implications for early intervention in bipolar disorder. J Ment Health. 2010;19 (2):113-26.
33. Mills NP, Delbello MP, Adler CM, Strakowski SM. MRI analysis of cerebellar vermal abnormalities in bipolar disorder. Am J Psychiatry. 2005;162(8):1530-2. (Pubitemid 41105570)
34. Hwang J, Lyoo IK, Dager SR, et al. Basal ganglia shape alterations in bipolar disorder. Am J Psychiatry. 2006;163(2):276-85. (Pubitemid 44480848)
35. Strakowski SM, DelBello MP, Sax KW, et al. Brain magnetic resonance imaging of structural abnormalities in bipolar disorder. Arch Gen Psychiatry. 1999;56(3):254-60. (Pubitemid 29125134)
36. Atmaca M, Ozdemir H, Yildirim H. Corpus callosum areas in firstepisode patients with bipolar disorder. Psychol Med. 2007;37 (5):699-704. (Pubitemid 46511094)
37. Barnea-Goraly N, Chang KD, Karchemskiy A, Howe ME, Reiss AL. Limbic and corpus callosum aberrations in adolescents with bipolar disorder: a tract-based spatial statistics analysis. Biol Psychiatry. 2009;66(3):238-44.
38. Brambilla P, Nicoletti M, Sassi RB, et al. Corpus callosum signal intensity in patients with bipolar and unipolar disorder. J Neurol Neurosurg Psychiatry. 2004;75(2):221-5. (Pubitemid 38183527)
39. Moorhead TW, McKirdy J, Sussmann JE, et al. Progressive gray matter loss in patients with bipolar disorder. Biol Psychiatry. 2007;62(8):894-900. (Pubitemid 47488221)
40. Frey BN, Zunta-Soares GB, Caetano SC, et al. Illness duration and total brain gray matter in bipolar disorder: evidence for neurodegeneration? Eur Neuropsychopharmacol. 2008;18(10):717-22.
41. Strakowski SM, DelBello MP, Zimmerman ME, et al. Ventricular and periventricular structural volumes in first-versus multiple-episode bipolar disorder. Am J Psychiatry. 2002;159 (11):1841-7. (Pubitemid 35283248)
42. Rajkowska G. Cell pathology in bipolar disorder. Bipolar Disord. 2002;4(2):105-16. (Pubitemid 34411273)
43. Hunsberger JG, Austin DR, Chen G, Manji HK. Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor- and mitochondrially-mediated plasticity. Brain Res. 2009;1293:76-84.
44. Schloesser RJ, Huang J, Klein PS, Manji HK. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology. 2008;33(1):110-33. (Pubitemid 350191320)
45. Kato T. Molecular neurobiology of bipolar disorder: a disease of 'mood-stabilizing neurons'? Trends Neurosci. 2008;31(10):495-503.
46. Perova T, Wasserman MJ, Li PP, Warsh JJ. Hyperactive intracellular calcium dynamics in B lymphoblasts from patients with bipolar I disorder. Int J Neuropsychopharmacol. 2008;11(2):185-96. (Pubitemid 351231827)
47. McCurdy RD, Féron F, Perry C, et al. Cell cycle alterations in biopsied olfactory neuroepithelium in schizophrenia and bipolar I disorder using cell culture and gene expression analyses. Schizophr Res. 2006;82(2-3):163-73. (Pubitemid 43290680)
48. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry. 2005;10(10):900-19. (Pubitemid 41486483)
49. So J, Warsh JJ, Li PP. Impaired endoplasmic reticulum stress response in B-lymphoblasts from patients with bipolar-I disorder. Biol Psychiatry. 2007;62(2):141-7. (Pubitemid 46963251)
50. Hayashi A, Kasahara T, Kametani M, et al. Aberrant endoplasmic reticulum stress response in lymphoblastoid cells from patients with bipolar disorder. Int J Neuropsychopharmacol. 2009;12 (1):33-43.
51. Manji H, Kato T, Di Prospero NA, et al. Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci. 2012;13 (5):293-307.
52. Du J, Wang Y, Hunter R, et al. Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci USA. 2009;106(9):3543-8.
53. Gong Y, Chai Y, Ding JH, Sun XL, Hu G. Chronic mild stress damages mitochondrial ultrastructure and function in mouse brain. Neurosci Lett. 2011;488(1):76-80.
54. Daban C, Vieta E, Mackin P, Young AH. Hypothalamic-pituitaryadrenal axis and bipolar disorder. Psychiatr Clin North Am. 2005;28(2):469-80.
55. Benes FM, Matzilevich D, Burke RE, Walsh J. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol Psychiatry. 2006;11(3):241-51.
56. Eastwood SL, Harrison PJ. Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins. Brain Res Bull. 2001;55(5):569-78. (Pubitemid 32888375)
57. Pfaffenseller B. Disfunção na Resposta ao Estresse do Retículo Endoplasmático em linfócitos de pacientes com Transtorno de Humor Bipolar. Dissertation. Porto Alegre: Universidade Federal do Rio Grande do Sul; 2012.
58. Bachmann RF, Schloesser RJ, Gould TD, Manji HK. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol. 2005;32(2):173-202. (Pubitemid 41397185)
59. Kim HW, Rapoport SI, Rao JS. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol Dis. 2010;37(3):596-603.
60. Fernandes BS, Gama CS, Ceresér KM, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45(8):995-1004.
61. Walz JC, Andreazza AC, Frey BN, et al. Serum neurotrophin-3 is increased during manic and depressive episodes in bipolar disorder. Neurosci Lett. 2007;415(1):87-9. (Pubitemid 46356723)
62. Walz JC, Magalhães PV, Giglio LM, et al. Increased serum neurotrophin-4/5 levels in bipolar disorder. J Psychiatr Res. 2009;43(7):721-3.
63. Rosa AR, Frey BN, Andreazza AC, et al. Increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder. Neurosci Lett. 2006;407(2):146-50. (Pubitemid 44404148)
64. Kapczinski F, Dal-Pizzol F, Teixeira AL, et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res. 2011;45(2):156-61.
65. Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci. 2009;34(4):263-71.
66. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, et al. Brainderived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol. 2009;12(4):447-58.
67. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry. 2000;57(10):925-35.
68. Grande I, Fries GR, Kunz M, Kapczinski F. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig. 2010;7(4):243-50.
69. Young LT. Neuroprotective effects of antidepressant and mood stabilizing drugs. J Psychiatry Neurosci. 2002;27(1):8-9. (Pubitemid 34478365)
70. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5(11):845-56. (Pubitemid 41746029)
71. Barbosa IG, Huguet RB, Mendonça VA, et al. Increased plasma levels of brain-derived neurotrophic factor in patients with longterm bipolar disorder. Neurosci Lett. 2010;475(2):95-8.
72. Barbosa IG, Rocha NP, Huguet RB, et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J Affect Disord. 2012;137(1-3):151-5.
73. Lin PY. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neurosci Lett. 2009;466(3):139-43.
74. Magalhães PV, Jansen K, Pinheiro RT, et al. A nested populationbased case-control study on peripheral inflammation markers and brainderived neurotrophic factor in early-stage mood disorders. Istambul: Presented at the 5th Biennial Conference of the International Society for Bipolar Disorders; 2012.
75. Hope S, Dieset I, Agartz I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res. 2011;45 (12):1608-16.
76. Tsai SY, Chung KH, Wu JY, et al. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord. 2012;136(1-2):110-6.
77. Barbosa IG, Huguet RB, Mendonça VA, et al. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2011;261(2):139-43.
78. Kunz M, Ceresér KM, Goi PD, et al. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev Bras Psiquiatr. 2011;33(3):268-74.
79. Söderlund J, Olsson SK, Samuelsson M, et al. Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. J Psychiatry Neurosci. 2011;36(2):114-8.
80. Barbosa IG, Rocha NP, Bauer ME, et al. Chemokines in bipolar disorder: Trait or state? Eur Arch Psychiatry Clin Neurosci. 2012. doi:10.1007/s00406-012- 0327-6.
81. Herberth M, Koethe D, Levin Y, et al. Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival. Proteomics. 2011;11(1):94-105.
82. Kato T. Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications. CNS Drugs. 2007;21(1):1-11. (Pubitemid 46072346)
83. Regenold WT, Phatak P, Marano CM, et al. Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis. Biol Psychiatry. 2009;65(6):489-94.
84. Halliwell B. Free radicals and antioxidants: updating a personal view. Nutr Rev. 2012;70(5):257-65.
85. Magalhães PV, Jansen K, Pinheiro RT, et al. Peripheral oxidative damage in early-stage mood disorders: a nested population-based case-control study. Int J Neuropsychopharmacol. 2011;19:1-8.
86. Andreazza AC, Kauer-Sant'anna M, Frey BN, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord. 2008;111(2-3):135-44.
87. Kunz M, Gama CS, Andreazza AC, et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7): 1677-81.
88. Yumru M, Savas HA, Kalenderoglu A, et al. Oxidative imbalance in bipolar disorder subtypes: a comparative study. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(6):1070-4.
89. Simon NM, Smoller JW, McNamara KL, et al. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry. 2006;60(5):432-5. (Pubitemid 44292160)
90. Elvsåshagen T, Vera E, Bøen E, et al. The load of short telomeres is increased and associated with lifetime number of depressive episodes in bipolar II disorder. J Affect Disord. 2011;135(1-3):43-50.
91. Berk M, Hallam KT, McGorry PD. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. J Affect Disord. 2007;100(1-3):279-81. (Pubitemid 46818451)
92. Kapczinski F, Dias VV, Kauer-Sant'Anna M, et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother. 2009;9(7):957-66.
93. McGorry PD, Purcell R, Hickie IB, et al. Clinical staging: a heuristic model for psychiatry and youth mental health. Med J Aust. 2007;187(7 Suppl):S40-2.
94. Magalhães PV, Dodd S, Nierenberg AA, Berk M. Cumulative morbidity and prognostic staging of illness in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEPBD). Australian & New Zealand Journal of Psychiatry. Aust N Z J Psychiatry. 2012. doi:10.1177/0004867412460593.
95. Magalhães PV, Kapczinski F, Nierenberg AA, Deckersbach T, Weisinger D, Dodd S, Berk M. Illness burden and medical comorbidity in the Systematic Treatment Enhancement Program for Bipolar Disorder. Acta Psychiatr Scand. 2012;125(4):303-308.
96. Reinares M, Papachristou E, Harvey P, Mar Bonnín C, Sánchez-Moreno J, Torrent C, Ayuso-Mateos JL, Ploubidis GB, Vieta E, Frangou S. Towards a clinical staging for bipolar disorder: Defining patient subtypes based on functional outcome. J Affect Disord. doi:10.1016/j.jad.2012. 06.005.
97. McGorry PD. Staging in neuropsychiatry: a heuristic model for understanding, prevention and treatment. Neurotox Res. 2010;18 (3-4):244-55.